標(biāo)題: Titlebook: Biosimilars for Cancer Treatment; A Promising Approach Shvetank Bhatt,Harish Dureja,Kamal Dua Book 2024 The Editor(s) (if applicable) and T [打印本頁] 作者: 珍珠無 時間: 2025-3-21 16:11
書目名稱Biosimilars for Cancer Treatment影響因子(影響力)
書目名稱Biosimilars for Cancer Treatment影響因子(影響力)學(xué)科排名
書目名稱Biosimilars for Cancer Treatment網(wǎng)絡(luò)公開度
書目名稱Biosimilars for Cancer Treatment網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Biosimilars for Cancer Treatment被引頻次
書目名稱Biosimilars for Cancer Treatment被引頻次學(xué)科排名
書目名稱Biosimilars for Cancer Treatment年度引用
書目名稱Biosimilars for Cancer Treatment年度引用學(xué)科排名
書目名稱Biosimilars for Cancer Treatment讀者反饋
書目名稱Biosimilars for Cancer Treatment讀者反饋學(xué)科排名
作者: 清真寺 時間: 2025-3-21 21:48 作者: Analogy 時間: 2025-3-22 00:51 作者: 改革運動 時間: 2025-3-22 07:58 作者: 博識 時間: 2025-3-22 10:20 作者: 改良 時間: 2025-3-22 15:49 作者: 災(zāi)禍 時間: 2025-3-22 19:01 作者: 可耕種 時間: 2025-3-23 00:21
U. M. Lütolf,P. Huguenin,C. Glanzmann for use in both the disease itself and as supportive drugs for cancer patients. The reduction in the treatment cost using trastuzumab biosimilars is approximately 20–30% lower in comparison to the costs using the reference product. The supportive drugs include haematopoietic growth factors like ery作者: 吞沒 時間: 2025-3-23 01:35 作者: 傲慢人 時間: 2025-3-23 09:02 作者: 多山 時間: 2025-3-23 13:23
https://doi.org/10.1007/978-3-319-23621-6f clinical studies that result in cost-effective drugs for patients. Thus, due to the biosimilars treatments are more tailored, with novel therapies that can be developed, but those seems to be challenging. So, the sponsors/investigators of biosimilars need to understand these challenges and refer t作者: Conflagration 時間: 2025-3-23 16:05
Flow Cytometric Immunophenotyping,of biosimilars, forming the basis for advancements in cancer treatment. These regulations also help maintain quality standards for affordable alternatives to biological drugs. This chapter emphasizes the regulatory considerations linked with biosimilars in cancer treatment, shedding light on the com作者: ANTIC 時間: 2025-3-23 19:59
https://doi.org/10.1007/978-3-319-23621-6g therapies. The objective of this transition is to provide economically viable alternatives for patients without compromising the fundamental characteristics of these pioneering drugs, which are essential in the treatment of cancer. Biosimilars are found to play an increasingly important role in ca作者: 極小量 時間: 2025-3-24 01:01
Immunobiology of Cancer,ary of the evidence for each of the three cancer immunoediting steps below. The main ideas of immunobiology in cancer are briefly reviewed in this chapter, along with the most recent developments in using the immune system to treat cancer. We also explore the function of inflammation and its dual ef作者: Pandemic 時間: 2025-3-24 06:12
Mechanism of Biosimilars for the Treatment of Cancer,ity, increased efficiency, or modernization when equipment has to be updated or replaced. Biosimilars have wide application in the medical field for the treatment of different chronic diseases like cancer, diabetes, autoimmune diseases, skin diseases, bowel diseases, and others. It is a good replace作者: Freeze 時間: 2025-3-24 08:29
Biosimilars in Colorectal Cancer,o ameliorate bone marrow suppression induced by chemotherapy. Other important BS used in CRC oncotherapy include trastuzumab-dkst, tocilizumab-bavi, adalimumab-aaty, and cetuxa. Multiple meta-analysis studies of randomized clinical trials indicated that BS are equivalent in efficacy to their referen作者: 放牧 時間: 2025-3-24 13:23
Biosimilar in Cervical Cancer,of biosimilars. It explores the profound implications of the widespread use of biosimilars in CC treatment, such as improved treatment coverage and the development of personalized treatment strategies. The chapter concludes by highlighting the revolutionary potential of biosimilars. It emphasizes th作者: backdrop 時間: 2025-3-24 16:36 作者: projectile 時間: 2025-3-24 21:58
Biosimilar in Lung Cancer,tiveness of biosimilar in the treatment of LC are explored, giving light on their potential to reduce financial burdens on healthcare systems and individuals alike..The review also emphasizes certain biosimilar drugs and their therapeutic applications in LC, with a focus on important trials and resu作者: Dysplasia 時間: 2025-3-24 23:27
A Recent Overview of the Growing Applications of Biosimilars in Pancreatic Cancer Management: Currearity to licensed biologics, established through laboratory testing focused on gauging similarity in pharmacodynamic and pharmacokinetic profiles. The authors of this chapter aim to offer an overview of the growing disease burden of pancreatic cancer and its pathogenesis, currently employed diagnost作者: GUILE 時間: 2025-3-25 05:56 作者: Apraxia 時間: 2025-3-25 11:30
Biosimilars in Hepatocellular Carcinoma, biosimilars in order to assess the clinical evidence regarding the safety and efficacy of biosimilars in the treatment of HCC. The goal of synthesizing the current data and identifying knowledge gaps is to help policymakers, researchers, and clinicians make well-informed decisions about the inclusi作者: commonsense 時間: 2025-3-25 13:27 作者: fulmination 時間: 2025-3-25 17:06
Biosimilars in Clinical Trials,f clinical studies that result in cost-effective drugs for patients. Thus, due to the biosimilars treatments are more tailored, with novel therapies that can be developed, but those seems to be challenging. So, the sponsors/investigators of biosimilars need to understand these challenges and refer t作者: 機制 時間: 2025-3-25 22:57 作者: PALL 時間: 2025-3-26 01:35
Future Scope of Biosimilars for the Treatment of Various Cancers,g therapies. The objective of this transition is to provide economically viable alternatives for patients without compromising the fundamental characteristics of these pioneering drugs, which are essential in the treatment of cancer. Biosimilars are found to play an increasingly important role in ca作者: cutlery 時間: 2025-3-26 08:19 作者: 平庸的人或物 時間: 2025-3-26 10:37 作者: 預(yù)知 時間: 2025-3-26 16:30 作者: Muffle 時間: 2025-3-26 18:58
Biosimilars in Colorectal Cancer, to target specificity, better outcome in chronic diseases, and excellent immunomodulators. Biosimilars (BS) are developed once biologics (reference product) patents expire to provide affordable accessible therapy to the patients. Extremely sensitive in vitro, in vivo, and clinical trials need to be作者: itinerary 時間: 2025-3-27 00:47 作者: Watemelon 時間: 2025-3-27 04:26
Biosimilars in Prostate Cancer,apter provides a comprehensive overview of prostate cancer, covering its etiology, pathogenesis, and current treatment approaches, with a focus on emerging biological therapies. The text delves into the diverse factors contributing to prostate cancer development, including age, race, genetics, diet,作者: 腐爛 時間: 2025-3-27 07:41
Biosimilars in Gastric Cancer,s and positioned it at the fourth spot in terms of worldwide fatalities. Since its inception, substantial study has been carried out to enhance the prognosis of GC therapy. The advancement of GC therapy in the past few years has rendered biosimilars a viable therapeutic option. Comparability testing作者: 簡潔 時間: 2025-3-27 11:16 作者: Sad570 時間: 2025-3-27 16:18 作者: flaunt 時間: 2025-3-27 20:58 作者: resuscitation 時間: 2025-3-27 22:19
Biosimilars in Hepatocellular Carcinoma,al settings as more affordable options to biologic medications. The present state of biosimilar development and use in the context of HCC is examined in detail in this study. This chapter discussed HCC, highlighting its rising frequency and the difficulties associated with the current treatment opti作者: Indigence 時間: 2025-3-28 02:37
Biosimilars in Ovarian Cancer,ggressive nature, and limited treatment options. Despite the research in conventional and targeted delivery, the management of ovarian cancer requires a novel therapeutic strategy to improve the quality of life. Biologics have been increasingly used for the management of ovarian cancer, but their hi作者: Allodynia 時間: 2025-3-28 09:53 作者: 諷刺 時間: 2025-3-28 12:59
Biosimilars in Clinical Trials,milars are the therapeutic alternatives to the reference biologic drugs, developed through rigorous regulatory requirements. When a commercial biologic loses patent protection, there are augmented opportunities for launch of biosimilars. On the basis of clinical trials, a biosimilar can meet the req作者: LAITY 時間: 2025-3-28 17:24
Regulatory Considerations of Biosimilars in Cancer,ions. Biosimilars, which are identical to the original biologic drugs, offer a promising opportunity to increase patient access to effective and more affordable cancer treatments. However, the rules and regulations governing biosimilars in oncology play a crucial role in ensuring their safety, effec作者: 朋黨派系 時間: 2025-3-28 20:56
Future Scope of Biosimilars for the Treatment of Various Cancers,d therapies for cancer. In this vein, biosimilars have revolutionized the cancer treatment options and have significant clinical outcomes. Because of the development of biologic medications, cancer treatment and supportive care have evolved dramatically. Biologics are increasingly being employed in 作者: 閑蕩 時間: 2025-3-28 23:01
Book 2024es, from colorectal and cervical to prostate, gastric, lung, pancreatic, breast, hepatocellular, ovarian, and blood cancers...It contains chapters that focus on the clinical trials of biosimilars, providing insights into the latest research and developments...This book serves as a valuable resource 作者: parasite 時間: 2025-3-29 03:45 作者: 運動吧 時間: 2025-3-29 10:55 作者: 繁榮地區(qū) 時間: 2025-3-29 11:46 作者: Brain-Waves 時間: 2025-3-29 17:56
Biotargeting in Metastatic Bone Diseasesions among physicians. Regulatory clarity, safety concerns, pharmacovigilance, automatic substitution policies, nomenclature, and labeling rules constitute crucial areas requiring attention as biosimilars evolve in the healthcare landscape.作者: 帽子 時間: 2025-3-29 22:40 作者: GEM 時間: 2025-3-30 02:01
cancer care.Explores the role of biosimilars in improving th.The book delves into the role of biosimilars in the field of cancer treatment. It also discusses the application of biosimilars in various cancer types, from colorectal and cervical to prostate, gastric, lung, pancreatic, breast, hepatocel作者: jettison 時間: 2025-3-30 06:09 作者: MIR 時間: 2025-3-30 12:05
Book 2024t focus on the clinical trials of biosimilars, providing insights into the latest research and developments...This book serves as a valuable resource for clinicians, researchers, and anyone seeking a comprehensive understanding of the intersection between biosimilars and cancer treatment..作者: 去世 時間: 2025-3-30 14:20 作者: 配偶 時間: 2025-3-30 16:50 作者: 小故事 時間: 2025-3-30 21:13 作者: COKE 時間: 2025-3-31 02:15
Prostate Cancer Bone Metastasisproved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicines. It works smoothly and efficiently for both acute and chronic illnesses. In the biological treatment of oncology, the high production cost causes burdensome to healthcare syst
